Trial Profile
A Phase 2, Investigator Initiated Study to Determine the Safety and Efficacy of TH-302 in Combination With Bevacizumab for Glioblastoma Following Bevacizumab Failure
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Apr 2020
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Evofosfamide (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- 09 Apr 2020 Status changed from active, no longer recruiting to completed.
- 25 Oct 2018 Planned End Date changed from 1 Jul 2018 to 1 Jul 2019.
- 25 Oct 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Jul 2019.